Thu Sep 19 06:58:52 UTC 2024: ## InspireMD Stock Receives Mixed Signals from Analysts
**New York, NY** – InspireMD (NYSE: NSPR), a medical device company specializing in vascular and coronary disease treatment, has garnered mixed opinions from analysts. Piper Sandler has reaffirmed its “overweight” rating for the company, setting a $4.50 price target, suggesting a potential upside of 71.10%.
However, StockNews.com has issued a “sell” rating for InspireMD in a newly released research report.
InspireMD reported earnings for the quarter ending August 6th, missing analysts’ estimates for earnings per share by $0.03. The company had revenue of $1.74 million, meeting analysts’ expectations. Analysts predict InspireMD will post -0.82 earnings per share for the current year.
Mesirow Financial Investment Management Inc. recently purchased a new stake in InspireMD, acquiring 30,000 shares valued at approximately $71,000. Hedge funds and other institutional investors currently own 44.78% of the company’s stock.
InspireMD focuses on developing and commercializing its MicroNet stent platform technology, primarily in Europe, Latin America, the Middle East, and Asia Pacific. The company offers a range of products for treating vascular and coronary diseases, including the CGuard carotid embolic prevention system and the SwitchGuard NPS device.
Despite the mixed opinions from analysts, investors will be closely monitoring InspireMD’s progress in the coming months to see how its technology and market share evolve.
First Piper 